Natural gums are economical, easily available, and useful as tablet binders. In the present investigation, an attempt was made to formulate Ofloxacin tablets using three natural binders, namely Acacia arabica, Hibiscus esculentus, and xanthan gum. Such six batches of Ofloxacin tablets were prepared by using different types and amounts of the natural binders by the wet granulation method. The ta...

Hyperphosphatemia has an important role in the development of secondary hyperparathyroidism and bone disease in patients with end-stage renal disease (ESRD). The most effective method of phosphate elimination lies with phosphate binders, the agent that more commonly used, calcium carbonate, is not an ideal binding agent. In this regard, calcium acetate has been reported to have more or at least...

From the Departments of Medicine (M.T., N.P.) and Public Health Sciences (M.T.) and the Division of Critical Care Medicine (N.P.), University of Alberta, Edmonton; and the Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB (B.M.) — both in Canada. Address reprint requests to Dr. Tonelli at 7-129 Clinical Science Bldg., 8440 112th St., Edmonton, AB T6B 2G3,...

BACKGROUND Hyperphosphatemia provides relevant and dangerous evidence of end-stage renal disease (ESRD) in patients undergoing periodic hemodialysis. The relationship between hyperphosphatemia and cardiovascular calcification, with the consequences of high morbidity and mortality after cardiovascular events, is well-defined. Hyperphosphatemia is treated by dietary limitation of phosphorus inges...

Introduction . Fibroblast growth factor type 23 (FGF-23) inhibits phosphate reabsorption and vitamin D hormone synthesis in the kidneys. There is a known relationship between FGF-23 levels serum phosphate, as well direct correlation hyperphosphatemia risk of cardiovascular events. Aim To evaluate associations bone mineral metabolism patients on renal replacement therapy (RRT) with hemo- periton...

Hyperphosphatemia in chronic kidney disease (CKD) patients is a risk factor for cardiovascular events, progressive kidney failure, and mortality. Improved therapeutic interventions to control hyperphosphatemia depend greatly on robust animal models that recapitulate the CKD disease process. Murine-based models of CKD as compared to rat models present significant advantages due to available gene...

OBJECTIVES The safety and efficacy of sevelamer hydrochloride in binding phosphate in patients with end-stage renal disease and its ability to attenuate the progression of cardiac calcification have been well documented but not the longer-term health and economic implications. Thus, a model of the predicted long-term consequences of sevelamer compared with calcium-based binders (acetate and car...

The incidence of cardiovascular events and mortality strongly correlates with serum phosphate in individuals with CKD. The Npt2b transporter contributes to maintaining phosphate homeostasis in the setting of normal renal function, but its role in CKD-associated hyperphosphatemia is not well understood. Here, we used adenine to induce uremia in both Npt2b-deficient and wild-type mice. Compared w...